Influence of (+)-cyanidanol-3 on the course of acute viral hepatitis
Cell Transformation, Viral
Receptors, Cell Surface
A double-bind study was conducted in 4 hospitals to test the effect of (+)-cyanidanol-3 (Catergen®) on the course of acute viral hepatitis. Activities of a number of enzymes, bilirubin levels and gamma-globulin concentrations, as well as elimination of HBs antigen in blood were measured serially in 73 patients with viral hepatitis, 37 being treated with the drug, 36 patients receiving a placebo. In addition, liver biopsies before and after treatment were compared (19 patients treated, 23 patients on placebo). There was no significant difference between the treatment and placebo groups with regard to morphological and biochemical changes.